Treatment, and Follow-up. Trimble EL. Ovarian Cancer Controversies: Examining the Options After Primary Treatment. MedGenMed 1(1), 1999. [formerly published in Medscape Women's Health eJournal 1(6 ...

An Australian-grown discovery has collared the culprit causing deadly ovarian cancer to return and spread after treatment.

These cells are typically more ... Jan. 24, 2024 — Results of a preclinical study offer hope for new treatment options in the medium term ovarian cancer is often very aggressive and responds ...

Amy Van Wyk had a seizure while on holiday in South Africa and was given the devastating news her ovarian cancer had ...

Stage IV ovarian cancer is a “distant” stage ... how well your cancer responds to treatment, and what treatment options are available to you all make a difference in your outcome.

Researchers around the world are trying to improve the diagnosis and treatment of ovarian cancer. Go to Cancer Research UK’s clinical trials database if you are looking for a trial for ovarian cancer ...

The pioneering treatment is ... have very limited options, with less than half responding to follow-up chemotherapy. The Dutch study involved 98 women with ovarian cancer whose first-line ...

There are different types of epithelial ovarian cancer. These include: As well as the type, the grade and stage of your ovarian cancer are very important. They help your specialist to decide what ...

potentially setting a new standard of care for patients with limited treatment options,” Dr Bilandzic said. The team’s research has been supported by the Ovarian Cancer Research Foundation (OCRF).

A new immunotherapy target called a cryptic antigen may be key in helping the immune system fight ovarian cancer.

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today is pleased to announce that its pioneering CAR-T ...

Patient enrollment set to begin at leading U.S. clinical trial sites, new drug product already deliveredTrial will advance ...